文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Melusin模拟肽通过调控LTCC通路增加LPS诱导心肌病期间的心室收缩力

Modulation of LTCC Pathways by a Melusin Mimetic Increases Ventricular Contractility During LPS-Induced Cardiomyopathy.
PubMed 文献 · Shock · 2022-03-09
一句话结论小鼠实验中,靶向LTCC的模拟肽R7W-MP可保留LPS攻击后心脏功能并显著改善生存,为脓毒症心肌病提供候选治疗。

本研究为前瞻性、随机、对照实验研究,使用Melusin过表达(MelOV)与野生型(MelWT)小鼠腹腔注射LPS。MelOV小鼠LPS攻击后心脏功能紊乱较轻,伴Akt和Gsk3-b磷酸化升高及LTCC密度恢复;药理抑制Akt可逆转Melusin依赖的心脏保护。在野生型小鼠LPS攻击后给予Akt变构抑制剂Arq092及靶向LTCC的模拟肽R7W-MP,R7W-MP保留心脏功能并显著改善生存。作者认为AKT/Melusin是LPS攻击后保留心脏功能的关键通路,R7W-MP是脓毒症心肌病的候选治疗。

要点

  • MelOV小鼠LPS攻击后心脏功能紊乱较轻,伴Akt和Gsk3-b磷酸化升高及LTCC密度恢复。
  • 药理抑制Akt活性可逆转Melusin依赖的心脏保护。
  • 野生型小鼠LPS攻击后给予靶向LTCC的模拟肽R7W-MP可保留心脏功能。
  • R7W-MP治疗显著改善LPS攻击后野生型小鼠的生存。
  • 作者认为细胞穿透性模拟肽R7W-MP是脓毒症心肌病的候选治疗。

适用人群与场景

  • LPS诱导心肌病的小鼠模型(MelOV与MelWT小鼠,以及接受LPS攻击的野生型小鼠)

处置流程与药物剂量

  • MelOV与MelWT小鼠腹腔注射LPS进行攻击。
  • 野生型小鼠在LPS攻击后接受Akt变构抑制剂Arq092或靶向LTCC的模拟肽R7W-MP治疗。

研究设计与关键结果

  • 研究类型:前瞻性、随机、对照实验研究;对象为MelOV与MelWT小鼠,LPS腹腔注射后经胸超声心动图评估心脏功能,并检测心肌LTCC、磷酸化Akt和磷酸化Gsk3-b表达。
  • MelOV小鼠LPS攻击后心脏功能紊乱较轻,保护作用与Akt和Gsk3-b磷酸化水平升高及LTCC密度恢复相关。
  • 药理抑制Akt活性可逆转Melusin依赖的心脏保护。
  • 在野生型小鼠LPS攻击后给予靶向LTCC的模拟肽R7W-MP可保留心脏功能,并显著改善生存。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、对照动物实验研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为AKT/Melusin是LPS攻击后保留心脏功能的关键通路。
  • 作者认为细胞穿透性模拟肽R7W-MP是脓毒症心肌病的候选治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Sepsis-induced cardiomyopathy is commonplace and carries an increased risk of death. Melusin, a cardiac muscle-specific chaperone, exerts cardioprotective function under varied stressful conditions through activation of the AKT pathway. The objective of this study was to determine the role of melusin in the pathogenesis of lipopolysaccharide (LPS)-induced cardiac dysfunction and to explore its signaling pathway for the identification of putative therapeutic targets.

METHODS AND RESULTS: Prospective, randomized, controlled experimental study in a research laboratory. Melusin overexpressing (MelOV) and wild-type (MelWT) mice were used. MelOV and MelWT mice were injected intraperitoneally with LPS. Cardiac function was assessed using trans-thoracic echocardiography. Myocardial expression of L-type calcium channel (LTCC), phospho-Akt and phospho-Gsk3-b were also measured. In separate experiments, wild-type mice were treated post-LPS challenge with the allosteric Akt inhibitor Arq092 and a mimetic peptide (R7W-MP) targeting the LTCC. The impact of these therapies on protein-protein interactions, cardiac function, and survival was assessed. MelOV mice had limited derangement in cardiac function after LPS challenge. Protection was associated with higher Akt and Gsk3-b phosphorylation and restored LTCC density. Pharmacological inhibition of Akt activity reversed melusin-dependent cardiac protection. Treatment with R7W-MP preserved cardiac function in wild-type mice after LPS challenge and significantly improved survival.

CONCLUSIONS: This study identifies AKT / Melusin as a key pathway for preserving cardiac function following LPS challenge. The cell-permeable mimetic peptide (R7W-MP) represents a putative therapeutic for sepsis-induced cardiomyopathy.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Arina P, Sorge M, Gallo A, et al. Modulation of LTCC Pathways by a Melusin Mimetic Increases Ventricular Contractility During LPS-Induced Cardiomyopathy. Shock. 2022. PMID: 35271535. doi:10.1097/SHK.0000000000001926

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。